| Date | Title | | | 05/08/13 | Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences| CAMBRIDGE, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 11:20 a.m. PT at the Encore at the Wynn in Las Vegas, NV; and at the UBS Global Healthcare Conference on Tuesday, May 21, 2013 at 8:00 a.m. ET at the Sheraton New York Hotel in New York, NY. Management will also host a fireside chat discu... |
|  | | 04/30/13 | Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results| CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2013.
First Quarter 2013 Financial Results
For the first quarter ended March 31, 2013, Idenix reported total revenues of $0.9 million, compared to total revenues of $35.6 million in the first q... |
| | | 04/24/13 | Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting| CAMBRIDGE, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported detailed resistance data from in vitro studies and from a three-day monotherapy clinical trial of IDX719, the Company's once-daily, potent, pan-genotypic NS5A inhibitor for the treatment of hepatitis C virus (HCV) infection. These data are being presented on Saturday... |
| | | 04/08/13 | Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)| CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it will present data on IDX719, the Company's pan-genotypic HCV NS5A inhibitor, at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) which is being held April 24 – 28, 2013 in Amsterdam, the Netherlands. Full abstracts can now... |
| |
|
